Researchers at Nationwide Children’s Hospital have received safe-to-proceed approval from the Food and Drug Administration (FDA) for Universal-Donor CD38KO CD33CAR-NK cells, to be studied in a forthcoming clinical trial. The Phase 1 trial will study the safety of the novel therapy in patients with advanced, high-risk acute myeloid leukemia (AML). About NMDP BioTherapies NMDP BioTherapies…

Return to autologous business driven by loyal cell and gene biotechnology customers seeking a comprehensive solution for improved supply chain and resource efficiencies with a white glove support model Industry-leading apheresis network support and managed logistics to enable consistent harvest and reliable delivery of autologous starting material and manufactured product MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known…

Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the NMDP…

Through this partnership, BlueSphere will treat patients with acute myeloid and lymphocytic leukemia, and myeloid dysplastic syndrome, who have active disease or are at high risk for relapse, with the goal of reducing the rate of relapse and graft versus host disease NMDP BioTherapies will provide bioinformatics consulting to help identify donors and will manage supply chain logistics to…

Study in conjunction with investigators from Labor Quade and the Johns Hopkins School of Medicine analyzed the longer-term stability of IDM analytes in uncentrifuged peripheral blood samples to allow for increased flexibility in donor sample processing. Study results indicate that broad use of blood processing parameters developed for the measure of metabolites appears to create…

First of Its Kind Clinical-Grade Leukopak Now Facilitates Easier Regulatory Filing with Access to a DMF and Identification of Additional Characteristics Required to Qualify Cord Blood Units as Starting Material for Manufacture of Cell and Gene Therapies MINNEAPOLIS, April 16, 2024 — NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell…

Groundbreaking Trial Seeks to Enhance Blood Cancer Treatment Efficacy and Safety MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) — NMDPSM (formerly known as the National Marrow Donor Program), home to the most diverse blood stem cell and marrow donor registry in the world, announced the enrollment of the first patient in the groundbreaking OPTIMIZE clinical trial today. The trial is…

Tom Hochuli will lead the organization as it renews its commitment to advancing cell and gene therapy MINNEAPOLIS , Jan. 30, 2024 — NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase. The appointment comes at a significant time for NMDP, which underwent…

Partnership will provide access to standardized and optimized apheresis collection, cryopreservation and bioprocessing processes throughout the U.S. and Europe  MINNEAPOLIS and NASHVILLE, Tenn. , Oct. 9, 2023 — NMDP BioTherapies℠, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport (NASDAQ: CYRX), a leading global provider of innovative products and services to the fast-growing cell &…

The NMDP BioTherapies Cord Blood Bank Alliance will work to grow the use of cord blood as a starting material to advance the development of live-saving cell therapies MINNEAPOLIS, July 10, 2023 –In recognition of Cord Blood Awareness Month, NMDP BioTherapies℠, an organization offering solutions for companies developing and commercializing cell and gene therapies, today…

Partnership has potential to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies MINNEAPOLIS, Minn. May 30, 2023 — NMDP BioTherapies℠, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced a working partnership with Garuda Therapeutics, a company working to create off-the-shelf,…

The dedicated webpage and complimentary white paper complement NMDP’s partner role in the CIBMTR® (Center for International Blood and Marrow Transplant Research®) and the CIBMTR’s Clinical Research Organization (CRO) services. MINNEAPOLIS, May 17, 2023 (GLOBE NEWSWIRE) — NMDP℠ and NMDP BioTherapies℠ launched a new web resource page and free white paper, “Paving the way to successful cell…

Expanded service offering specializes in the design, implementation and oversight of cellular therapy clinical trials to speed patient access to life-saving treatments MINNEAPOLIS, Minn. January 17, 2023 — NMDP BioTherapies℠, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced it is offering CIBMTR® (Center for International Blood and Marrow Transplant…

New service providing real-world, data-driven insights in cell and gene therapy to guide the development of safe and effective allogeneic therapies. MINNEAPOLIS, Minn. December 14, 2022 — Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services, which blends the unique expertise,…

Chris McClain, Senior Vice President, offers regional support for companies seeking high-quality source material for breakthrough allogeneic therapies. MINNEAPOLIS, Minn. October 25, 2022 — Be The Match BioTherapies® today announced expanded support for clients in the Northern California region. Chris McClain, Senior Vice President, will work from the San Francisco area to support an expanding client…

The Be The Match Registry® includes more than 266,000 fully characterized CBUs, allowing for therapy-matched unit identification.  MINNEAPOLIS, Minn. August 9, 2022 – (BUSINESS WIRE) — Be The Match BioTherapies® announced it is now providing cryopreserved Cord Blood Units as allogeneic cell therapy starting material for non-clinical, clinical, and commercial use. The Be The Match…

The strategic partnership will leverage Be The Match BioTherapies’ optimized solutions to accelerate development timelines and expand trial access for Chimeric’s CHM 1101 (CLTX CAR T) program Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered a strategic partnership with…

Relationship Will Leverage Be The Match BioTherapies’ Expertise and Expansive Donor Registry to Provide Healthy Donor Cells in Support of Atara’s Allogeneic T-cell Platform MINNEAPOLIS, Minn. & SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022 – (BUSINESS WIRE) – Be The Match BioTherapies® and Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced an extension of their collaboration…

MINNEAPOLIS and SAN FRANCISCO, Dec. 08, 2021 (GLOBE NEWSWIRE) — Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies (CGTs), and Vineti, the provider of the leading digital enterprise platform for cell and gene therapy supply chains, today announced a collaboration to develop joint solutions that simplify and scale…

Cellevolve’s collaboration with Australia-based QIMR Berghofer will accelerate the development and commercialization of a novel, bioengineered JC virus specific T-cell (VST) therapy for PML, a highly disabling disease of the central nervous system (CNS). Off-the-shelf, allogeneic cell therapies may offer many advantages, including faster delivery to patients with rapidly progressing illnesses like PML Additionally, Cellevolve…

Be The Match BioTherapies will provide streamlined supply chain services in support of Orchard’s commercial-stage gene therapy in Europe MINNEAPOLIS, Minn., March 3, 2021 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership with Orchard Therapeutics (Nasdaq: ORTX), a global…

Be The Match BioTherapies® as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy (CGT) supply chain support Lonza as a preferred partner for CDMO services for Be The Match BioTherapies’ clients The partnership reinforces Lonza’s Vein-to-Vein network and Be The Match BioTherapies’ apheresis network and cell therapy…

Organizations to work together to integrate Be The Match BioTherapies’ existing cell therapy infrastructure to manage the supply chain for potential commercialization of omidubicel   BOSTON, Mass. and MINNEAPOLIS, Minn., Oct. 13, 2020 – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies®, an organization offering solutions for…

Genetically engineered therapy treats relapsed or refractory large B-cell lymphoma, a blood cancer Milwaukee, WI, Sept. 8, 2020 – The CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced that it has reached a study enrollment goal two years early, and 1,500 patients have now enrolled in the post-marketing safety study for Yescarta®…

Be The Match BioTherapies will Provide Allogeneic Cellular Source Material to NantKwest for Clinical Trial Addressing Primary Cause of COVID-19 Fatality MINNEAPOLIS, Minn., and EL SEGUNDO, Calif., May 19, 2020 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation,…

A message from Chris McClain, Sr. Vice President The 2019 novel coronavirus (COVID-19) situation continues to change rapidly throughout the United States and the world. We are closely monitoring developments and evaluating potential impact to our client support. The activities and business of our clients are very important to us. We are working with our…

MINNEAPOLIS, Minn., February 2020 – Be The Match BioTherapies® participated in Phacilitate: Leaders World 2020 in Miami, Fla. The conference offered many opportunities for the team to connect with and learn from companies and organizations leading innovation and acceleration in the cell and gene therapy industry. The effect of cellular starting material quality was clearly…

Minneapolis, MN, and Durham, NC, Feb. 19, 2020 – The CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence. IQVIA (NYSE: IQV) is a company known worldwide for its expertise in building technology solutions customized for global research networks engaged in complex data exchange for clinical outcomes registries.  The CIBMTR is a long-standing research collaboration between the National…

Post-Marketing Study with a Larger Proportion of Older and More Difficult-to-Treat Patients Demonstrates Comparable Safety and Efficacy Data to ZUMA-1 Pivotal Trial Results Presented at the American Society of Hematology (ASH) Annual Meeting Orlando, Fla., Dec. 9, 2019 — Kite, a Gilead Company (Nasdaq: GILD), and the CIBMTR® (Center for International Blood and Marrow Transplant…

Multi-Year Observational Study Designed to Evaluate Outcomes of Patients with Hematologic Malignancies Who Undergo Allogeneic Bone Marrow Transplantation Boston, Mass. and Milwaukee, Wis. – Sept. 11, 2019 – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the entry into…

Alliance will support the clinical progression of Celyad’s non-gene edited allogeneic CAR-T candidates MINNEAPOLIS, USA and MONT-SAINT GUIBERT, BELGIUM, Sept. 10, 2019 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on…

Partnership will accelerate access to novel therapeutics for patients with devastating diseases MINNEAPOLIS and PHILADELPHIA, July 9, 2019—Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company, today announced a partnership to accelerate patient access to life-saving cell therapies.…

Second annual summit discusses standardizing key cell therapy processes including starting material collection, software platforms and patient outcomes reporting infrastructure MINNEAPOLIS, Minn., June 27, 2019 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and the CIBMTR® (Center for International Blood and Marrow Transplant Research), a…

Minneapolis, US, and Cardiff, UK, June 18, 2019 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and TrakCel, a software developer for cell and gene therapy supply chain tracking and orchestration systems, today announce a collaboration that will provide integrated solutions for companies developing cell…

Collaboration will support Phase III clinical trial of cell therapy product ATIR101™ for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 — Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Kiadis Pharma N.V. (“Kiadis”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announced a…

Be The Match BioTherapies will provide end-to-end support services to accelerate clinical development of Poseida’s autologous BCMA and PSMA CAR-T programs MINNEAPOLIS, Minn., May 14, 2019 – Be The Match BioTherapies®, a subsidiary of the National Marrow Donor Program® (NMDP)/Be The Match® that offers integrated services and software to manage the collection and delivery of…

Collaboration Aims to Expand the Use of Bone Marrow Transplant to Treat Hematologic Malignancies and Serious Blood Disorders  BOSTON, Mass. and MINNEAPOLIS, Minn., Jan. 22, 2019 – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies®, a subsidiary of the National Marrow Donor Program®/Be The Match® offering…

Collaboration aims to streamline access to authorized collection and processing centers MINNEAPOLIS—Dec. 20, 2018—Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced a collaboration with the National Health Service Blood and Transplant (NHSBT), the public organization responsible for the donation and storage of blood in…

New program to provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks while minimizing quality system audit burden on centers MINNEAPOLIS, Nov. 8, 2018 – Be The Match BioTherapies, an organization offering integrated platforms and software to manage the collection and delivery of cellular therapies, today…

Minneapolis, Minn. & Irvine, Calif., October 3, 2018 – Be The Match BioTherapies®, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end…

Milwaukee, Wis., September 14, 2018 – A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T-cell (CAR-T) therapies has been established between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Novartis. Under the terms of the collaboration, CIBMTR will collect long-term safety and efficacy data from…

MINNEAPOLIS – August 2018 Be The Match BioTherapies® will be presenting at three upcoming conferences in Boston: the Immuno-Oncology Summit, CAR-TCR Summit, and Cell & Gene Therapy Bioprocessing & Commercialization. On Thursday, Aug. 30, at 10:45 a.m., Amy Hines, RN, BSN, Director, Collection Network Management, will present, “Facing the Challenges of Apheresis Network Management,” at…

MINNEAPOLIS, Minn., June 28, 2018 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cellular therapies, today announced the appointment of Mark Flower as Vice President, Business Development and Strategic Partnerships, and Erin Rasch as Senior Director, Sales and New Business Development. “We are delighted to expand our business development…

Minneapolis, Minn., May 17, 2018 – A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research®), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community…

Organization announces second investment in Magenta with participation in Series C financing round Amy Ronneberg, president of Be The Match BioTherapies, appointed to Magenta’s Board of Directors MINNEAPOLIS, Minn., and CAMBRIDGE, Mass., April 9, 2018 – Be The Match BioTherapies®, an organization offering solutions for companies developing and delivering cellular therapies, today announced that it…

MINNEAPOLIS, Minn., March 27, 2018 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cellular therapies, today announced the appointment of Chris McClain, MBA, to Vice President, New Business Development and Sales, and Steven Devine, MD, a renowned stem cell transplant physician, as Medical Director. In addition, the company appointed…

MINNEAPOLIS – Jan. 2018 Be The Match BioTherapies®, an organization offering solutions for delivering cellular therapies, today announced that it has invested in Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy. The investment was announced today as part of Tmunity’s…

Software to improve the end-to-end supply chain management of autologous cell therapies leverages parent company’s 30-year experience managing stem cell transplants worldwide MINNEAPOLIS — Oct. 4, 2017 Be The Match BioTherapies®, an organization offering solutions for delivering autologous and allogeneic cellular therapies, today announced the launch of a new, implementation-ready technology platform for cell and…

MINNEAPOLIS – June 2017 An Associate Bioinformatics Scientist for Be The Match BioTherapies® and the National Marrow Donor Program® (NMDP)/Be The Match® attended the first Artificial Intelligence (AI) Hackathon at Google’s Launchpad in San Francisco. Wei Wang joined about 150 AI engineers and life sciences researchers on-site as they focused on using AI and machine…

Strategic partnership aims to expand the use of stem cell transplant to immune and blood-based diseases MINNEAPOLIS-May 2, 2017 Be The Match BioTherapies®, an organization offering solutions for delivering autologous and allogeneic cellular therapies, today announced that it has entered into a strategic partnership with Magenta Therapeutics, a biotechnology company developing therapies to improve and…

New Subsidiary to Partner With Organizations Pursuing Life-Saving Cellular Therapies MINNEAPOLIS-Jan. 2016 National Marrow Donor Program® (NMDP)/Be The Match®, the national organization that connects patients with their donor match for a life-saving bone marrow or umbilical cord blood transplant, today announced the formation of Be The Match BioTherapiesSM, a subsidiary that will focus on partnering…